Searching for an oasis from the vasomotor symptoms of menopause: Could elinzanetant be the answer?
| Autor: | Millstine DM; Women's Health Internal Medicine, Mayo Clinic, Department of Medicine, Scottsdale, AZ, USA., Kling JM; Women's Health Internal Medicine, Mayo Clinic, Department of Medicine, Scottsdale, AZ, USA; Mayo Clinic Center for Women's Health, Mayo Clinic, Rochester, MN, USA. Electronic address: kling.juliana@mayo.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Med (New York, N.Y.) [Med] 2024 Dec 13; Vol. 5 (12), pp. 1459-1460. |
| DOI: | 10.1016/j.medj.2024.11.008 |
| Abstrakt: | In the OASIS 1 and 2 trials, elinzanetant, a selective neurokinin-1,3 receptor antagonist, was compared to placebo in women aged 40-65 with moderate to severe menopausal vasomotor symptoms (VMSs) at multiple sites over 26 weeks. Elinzanetant significantly reduced VMS frequency and severity and improved sleep disturbance and menopause-related quality of life compared to placebo with few adverse side effects. 1 . Competing Interests: Declaration of interests J.M.K. has no conflicts of interest directly related to the subject of this manuscript. However, over the past 24 months she has had the following conflicts of interest. She has received CME or non-CME honoraria from Vindico, AiCME, Contemporary Forums, APS, City of Mesa, Evolve Medical Education, and EPG Health. She has also been a consultant for Elsevier and Everyday Health. (Copyright © 2024 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|